Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CRMD vs LBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CRMD 4 – 2 LBRX Matrix Metrics: CRMD 6 – 4 LBRX

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over LB Pharmaceuticals Inc (LBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas LBRX carries 46.5/100 (HOLD) at $39.15 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. LBRX 46.5/100 HOLD) and 1.22β · 103% Vol risk profile, whereas LBRX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile LBRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs LBRX
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap $370.6M
TTM Revenue $1.01B
Forward P/E 29.5x
Beta / 30D Vol 1.22β · 103% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.1%), weak momentum, RSI 27
RSI-14: 26.8 · SMA20: $6.18 · SMA50: $7.04
LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$39.15
-8.93% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.10β · 67% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -6.3%) with fading momentum, RSI 46
RSI-14: 45.8 · SMA20: $40.95 · SMA50: $39.87

6-Pillar Scorecard Institutional Category Breakdown (CRMD 4 – 2 LBRX)

Columns: Metric · CRMD · LBRX
1. Valuation Multiples CRMD
Forward P/E 29.5x N/M
Trailing P/E 2.4x N/M
PEG Ratio 3.32x N/M
EV / Revenue N/M N/M
2. Growth & Scale LBRX
Revenue Growth (YoY) -47.7% +0.0%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $1.01B N/A
Market Cap $370.6M $1.4B
3. Profitability & Quality CRMD
Gross Margin 87.4% N/A
Operating Margin 41.0% 0.0%
Net Profit Margin 15.5% 0.0%
Return on Equity (ROE) 15.3% -38.8%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $755M -$144M
Cash Flow Margin 74.6% N/A
Net Cash / Leverage $514M Net Cash $210M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LBRX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 53.2% (22nd %ile) 71.9% (4th %ile)
Put/Call OI Skew 2.32x (Put-Skewed) 0.50x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 46.4% of Rev ($469M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (6) vs LBRX (4)
Institutional Metric CRMD LBRX Criterion Row Edge
Market Capitalization
Scale
$370.6M $1.4B Larger Scale LBRX
Trailing P/E Ratio
Valuation
2.4x N/M Lower Multiple CRMD
Forward P/E Ratio
Valuation
29.5x N/M Lower Multiple CRMD
Revenue Growth (YoY)
Growth
-47.7% +0.0% Higher Growth LBRX
Operating Margin (TTM)
Profitability
41.0% 0.0% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% -38.8% Higher ROE CRMD
52-Week Range Position
Momentum
1% ($5–$13) 69% ($14–$50) Stronger Trend LBRX
Beta / 30D Volatility
Risk Regime
1.22β · 103% Vol 1.10β · 67% Vol Lower Realized Risk LBRX
Unified Institutional Score
Composite Signal
55.5 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$1.01B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.32x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$755M ($514M Net Cash) -$144M ($210M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LBRX +37.26 pp
CRMD: -36.38% · LBRX: +0.88%
3M Horizon LBRX +24.89 pp
CRMD: -44.89% · LBRX: -20.0%
6M Horizon LBRX +83.52 pp
CRMD: -39.96% · LBRX: +43.56%
1Y Horizon LBRX +220.81 pp
CRMD: -58.23% · LBRX: +162.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs LBRX. Trailing 12-month operating profitability (CRMD 41.0% vs LBRX 0.0%) and valuation multiples (CRMD 29.5x vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 29.5x
LBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-38.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
110d in phase · OBV DISTRIBUTION
Current IV 53.2%
IV Percentile 22nd %ile
Put/Call OI Skew 2.32x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LBRX CONSOLIDATION
63d in phase · OBV DISTRIBUTION
Current IV 71.9%
IV Percentile 4th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $370.6M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($469M)
90D Engineering Disclosures 0 Published
LBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMD vs LBRX Key Questions & Quantitative Answers

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over LB Pharmaceuticals Inc (LBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas LBRX carries 46.5/100 (HOLD) at $39.15 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. LBRX 46.5/100 HOLD) and 1.22β · 103% Vol risk profile, whereas LBRX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile LBRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LBRX leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with LBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMD generates $1.01B in USD-normalized revenue versus N/A for LBRX. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($469M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LBRX.

CRMD screens cheaper on headline valuation multiples. CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas LBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus LBRX (-38.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk). By comparison, LBRX carries 71.9% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.10β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.